<DOC>
	<DOCNO>NCT00357734</DOCNO>
	<brief_summary>The purpose study ass long-term safety profile secondary objective estimate clinical benefit ZD1839 ( gefitinib ) .</brief_summary>
	<brief_title>Iressa Follow-up Trial</brief_title>
	<detailed_description />
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Provision write informed consent participate trial . Female male age 18 year . Patients previously diagnose cancer treat ZD1839 parent ZD1839 clinical trial may benefit continuation Known severe hypersensitivity ZD1839 Concomitant use phenytoin , carbamazepine , rifampicin , barbiturate , St John 's Wort . Withdrawal parent ZD1839 trial tumor progress</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>lung cancer</keyword>
	<keyword>breast cancer</keyword>
</DOC>